Sign in Subscribe
Class action lawsuits

Cytokinetics Class Action Lawsuit Filed: Investors Suffered Damages

Strategic Insights

— 2 min read

Investors who purchased Cytokinetics common stock between December 27, 2023, and May 6, 2025, may be entitled to compensation without payment of any out-of-pocket fees or costs through a contingency fee arrangement. The lawsuit claims that defendants made false and/or misleading statements regarding the timeline for the New Drug Application (NDA) submission and approval process for aficamten. Specifically, defendants represented that Cytokinetics expected approval from the U.S. Food and Drug Administration (FDA) for its NDA for aficamten in the second half of 2025, based on a September 26, 2025, Prescription Drug User Fee Act (PDUFA) date, and failed to disclose material risks related to Cytokinetics' failure to submit a Risk Evaluation and Mitigation Strategy (REMS) that could delay the regulatory process.

Key Takeaways:

  • The class action lawsuit was filed by Rosen Law Firm on behalf of purchasers of Cytokinetics common stock between December 27, 2023, and May 6, 2025.
  • The lawsuit claims that defendants made false and/or misleading statements regarding the NDA submission and approval process for aficamten.
  • Specifically, defendants represented that Cytokinetics expected approval from the FDA for its NDA for aficamten in the second half of 2025.
  • The lawsuit alleges that defendants failed to disclose material risks related to Cytokinetics' failure to submit a REMS that could delay the regulatory process.
  • Investors who purchased Cytokinetics common stock during the Class Period may be entitled to compensation without payment of any out-of-pocket fees or costs through a contingency fee arrangement.
  • The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation.
  • The firm has recovered hundreds of millions of dollars for investors in 2019 alone, securing over $438 million.

Statistics:

  • The class action lawsuit was filed on behalf of investors who purchased Cytokinetics common stock between December 27, 2023, and May 6, 2025.
  • The lawsuit claims that investors suffered damages when the true details of the NDA submission and approval process for aficamten entered the market.
  • Cytokinetics expected approval from the FDA for its NDA for aficamten in the second half of 2025, based on a September 26, 2025, PDUFA date.
  • The lawsuit alleges that Cytokinetics' failure to submit a REMS could delay the regulatory process.

Sources:

  • GlobeNewswire, "Rosen Law Firm Announces Filing of Securities Class Action Lawsuit Against Cytokinetics, Inc."
  • LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm
  • Twitter: https://twitter.com/rosen_firm
  • Facebook: https://www.facebook.com/rosenlawfirm/
  • The Rosen Law Firm, P.A. - 275 Madison Avenue, 40th Floor, New York, NY 10016
  • Phone: (212) 686-1060, Toll Free: (866) 767-3653, Fax: (212) 202-3827, Email: case@rosenlegal.com
  • Website: www.rosenlegal.com

Read more